Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice

Total Page:16

File Type:pdf, Size:1020Kb

Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice 0031-6997/06/5803-521–590$20.00 PHARMACOLOGICAL REVIEWS Vol. 58, No. 3 Copyright © 2006 by The American Society for Pharmacology and Experimental Therapeutics 60305/3134736 Pharmacol Rev 58:521–590, 2006 Printed in U.S.A Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice SHARON J. GARDINER AND EVAN J. BEGG Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand Abstract ............................................................................... 523 I. Introduction/perspective ................................................................. 523 A. Background on pharmacogenetics ..................................................... 524 B. Pathways with genetic variation that may be important clinically ........................ 526 II. Cytochrome P450 ....................................................................... 526 A. CYP2D6 ............................................................................ 526 1. Tricyclic antidepressants .......................................................... 526 a. Amitriptyline (tertiary)/nortriptyline (secondary) .................................. 529 b. Imipramine (tertiary)/desipramine (secondary).................................... 530 c. Clomipramine (tertiary)/desmethylclomipramine (secondary) ....................... 531 d. Doxepin (tertiary)/desmethyldoxepin (secondary) .................................. 531 2. Selective serotonin reuptake inhibitors.............................................. 531 a. Fluoxetine .................................................................... 531 b. Paroxetine .................................................................... 531 c. Other selective serotonin reuptake inhibitors ..................................... 531 3. Other antidepressants............................................................. 532 a. Maprotiline ................................................................... 532 b. Mianserin ..................................................................... 532 c. Venlafaxine ................................................................... 532 4. Antidepressants (in general) and clinical outcomes ................................... 532 5. Antipsychotics.................................................................... 533 a. Chlorpromazine................................................................ 533 b. Haloperidol.................................................................... 533 c. Perphenazine.................................................................. 533 d. Thioridazine................................................................... 533 e. Zuclopenthixol ................................................................. 534 f. Atypical antipsychotics ......................................................... 534 g. Antipsychotics (in general) and clinical outcomes.................................. 534 6. Antiarrhythmics .................................................................. 534 a. Propafenone ................................................................... 535 b. Flecainide..................................................................... 535 c. Mexiletine .................................................................... 535 7. ␤-blockers........................................................................ 535 a. Carvedilol ..................................................................... 535 b. Metoprolol .................................................................... 536 c. Propranolol.................................................................... 536 d. Timolol ....................................................................... 537 8. Opioid analgesics ................................................................. 537 a. Codeine ....................................................................... 537 b. Dihydrocodeine ................................................................ 537 c. Tramadol ..................................................................... 538 Address correspondence to: Sharon Gardiner, Department of Medicine, Christchurch School of Medicine, Private Bag 4345, Christchurch, New Zealand. E-mail: [email protected] Funding was via a Top Achiever Doctoral (Tertiary Education Commission, New Zealand) scholarship (to S.G.). Article, publication date, and citation information can be found at http://pharmrev.aspetjournals.org. doi:10.1124/pr.58.3.6. 521 522 GARDINER AND BEGG d. Other opioids .................................................................. 538 9. Antiemetics ...................................................................... 538 10. Antihistamines ................................................................... 538 11. Other drugs ...................................................................... 538 a. Atomoxetine................................................................... 538 b. Perhexiline.................................................................... 539 c. Phenformin ................................................................... 539 d. Tolterodine.................................................................... 539 12. Summary of CYP2D6 ............................................................. 539 B. CYP2C9 ............................................................................ 540 1. Coumarin anticoagulants .......................................................... 541 a. Warfarin ...................................................................... 542 b. Acenocoumarol ................................................................ 543 c. Phenprocoumon................................................................ 543 2. Sulfonylurea drugs................................................................ 543 a. Tolbutamide................................................................... 543 b. Glyburide ..................................................................... 543 c. Glimepiride ................................................................... 543 d. Glipizide and gliclazide ......................................................... 544 3. Angiotensin II blockers............................................................ 544 a. Losartan ...................................................................... 544 b. Candesartan .................................................................. 544 c. Irbesartan .................................................................... 545 4. Nonsteroidal anti-inflammatory drugs .............................................. 545 a. Diclofenac..................................................................... 545 b. Ibuprofen ..................................................................... 545 c. Oxicams ...................................................................... 545 d. Celecoxib...................................................................... 545 e. Other selective cyclooxygenase-2 inhibitors ....................................... 546 f. Nonsteroidal anti-inflammatory drugs (in general) and clinical outcomes ............ 546 5. Phenytoin........................................................................ 546 6. Other drugs ...................................................................... 547 7. Summary of CYP2C9 ............................................................. 547 C. CYP2C19 ........................................................................... 548 1. Proton pump inhibitors............................................................ 548 2. Benzodiazepines .................................................................. 551 3. Tricyclic antidepressants .......................................................... 552 4. Selective serotonin reuptake inhibitors.............................................. 552 5. Barbiturates ..................................................................... 552 6. Proguanil ........................................................................ 553 7. Phenytoin........................................................................ 553 8. Moclobemide ..................................................................... 554 9. Other drugs ...................................................................... 554 10. Summary of CYP2C19 ............................................................ 554 D. Other cytochromes P450 ............................................................. 554 1. CYP2B6 ......................................................................... 554 a. Bupropion..................................................................... 555 b. Efavirenz ..................................................................... 555 2. CYP2C8 ......................................................................... 555 a. Paclitaxel ..................................................................... 556 b. Ibuprofen ..................................................................... 556 c. Repaglinide ................................................................... 556 d. Thiazolidinediones ............................................................. 557 e. Cerivastatin ................................................................... 557 f. Summary ..................................................................... 557 3. CYP3A5 ......................................................................... 557 a. Midazolam .................................................................... 558 PHARMACOGENETICS, DRUG
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Different Role of CA1 5HT3 Serotonin Receptors on Memory $FTXLVLWLRQ'H¿FLW,QGXFHGE\7RWDO 76' DQG5(06OHHS 'HSULYDWLRQ 56'
    Z. Eydipour, G. Vaezi, M. Nasehi, et al. Original Article Different Role of CA1 5HT3 Serotonin Receptors on Memory $FTXLVLWLRQ'H¿FLW,QGXFHGE\7RWDO 76' DQG5(06OHHS 'HSULYDWLRQ 56' Zainab Eydipour PhD1, Gholamhassan Vaezi PhD1, Mohammad Nasehi PhDƔ, Seyed-Ali Haeri-Rouhani PhD3, Mohammad-Reza Zarrindast PhDƔ Abstract Background: Serotonin receptors such as 5-HT3 plays critical role in regulation of sleep, ZDNH cycle and cognitive process. Thus, we investigated the role of CA1 5HT3 serotonin receptors in memory acquisition GH¿FLW induced by total sleep deprivation (TSD; for 24 hour) and REM sleep deprivation (RSD; for 24 hour). Pain perception and locomotor activity were also assessed as factors that may affect the memory process. Methods: 0RGL¿HG water box and multi-platform apparatus were used to induce TSD or RSD, respectively. Passive avoidance, hot plate and open ¿HOG devices were used for assessment of memory acquisition, pain and locomotor activity, respectively. Results: Totally, 152 male Wistar rats were used in the study. Pre-training, intra-CA1 injection of 5-HT3 receptor agonist Chlorophenylbiguanide (Mchl; 0.01 and 0.001 μg/rat; P < 0.001) and antagonist Y-25130 (0.1 μg/rat; P < 0.001) reduced memory acquisition and did not alter pain response, while higher dose of both drugs increased locomotor activity in normal rats. Both TSD and RSD reduced memory acquisition (P < 0.001) and did not alter locomotor activity, while TSD (P < 0.001) but not RSD induced analgesia effect. The amnesia induced by TSD was restored by subthreshold dose of Y25130 (0.001 μg/rat; P < 0.001) but not Mchl (0.0001 μg/rat), while both drugs reversed TSD-induced analgesia effect (P < 0.01 for Mchl and P < 0.05 for Y25130), and Y25130 increased locomotor activity in TSD rats (P < 0.05).
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • Investigating the Pharmacology of Novel 5-HT3 Receptor Ligands; with the Potential to Treat Neuropsychiatric and Gastrointestinal Disorders
    Investigating the pharmacology of novel 5-HT3 receptor ligands; with the potential to treat neuropsychiatric and gastrointestinal disorders by Alexander Roberts A thesis submitted to the University of Birmingham for the Degree of Doctor of Philosophy Institute of Clinical Sciences College of Medical and Dental Sciences University of Birmingham February 2020 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. Abstract The 5-hydroxytryptamine (5-HT; serotonin) 5-HT3 receptor is an excitatory ligand- gated ion channel expressed in for example the brain and the gastrointestinal tract. Two major subtypes of the receptor have been studied in the most detail; the homomeric 5-HT3A receptor and the heteromeric 5-HT3AB receptor. 5-HT3 receptor antagonists are used clinically to treat chemotherapy induced and post-operative nausea and vomiting, and demonstrate symptomatic relief in diarrhoea-predominant irritable bowel syndrome (IBS-d); but unfortunately, these medications cause adverse effects such as constipation or rarely ischemic colitis in the latter condition. This study has characterised the pharmacology of two structurally distinct 5-HT3 receptor partial agonists (vortioxetine and CSTI-300); and identified the unique binding properties of the cryptic orthosteric modulator 5-chloroindole (Cl-indole) for the human (h) 5-HT3 receptor.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Proteostasis of Glial Intermediate Filaments: Disease Models, Tools, and Mechanisms
    PROTEOSTASIS OF GLIAL INTERMEDIATE FILAMENTS: DISEASE MODELS, TOOLS, AND MECHANISMS Rachel Anne Battaglia A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Cell Biology and Physiology in the School of Medicine. Chapel Hill 2021 Approved by: Natasha T. Snider Carol Otey Keith Burridge Douglas Cyr Mohanish Deshmukh Damaris Lorenzo i © 2021 Rachel Anne Battaglia ALL RIGHTS RESERVED ii ABSTRACT Rachel Anne Battaglia: Proteostasis of Glial Intermediate Filaments: Disease Models, Tools, and Mechanisms (Under the direction of Natasha T. Snider) Astrocytes are a major glial cell type that is crucial for the health and maintenance of the Central Nervous System (CNS). They fulfill diverse functions, including synapse formation, neurogenesis, ion homeostasis, and blood brain barrier formation. Intermediate filaments (IFs) are components of the astrocyte cytoskeleton that support many of these functions in healthy individuals. However, upon cellular stress or genetic mutations, IF proteins are prone to accumulation and aggregation. These processes are thought to contribute to disease pathogenesis of different tissue-specific disorders, but therapeutic targeting of IFs is hindered by a lack of pharmacological tools to modulate their assembly and disassembly states. Moreover, the mechanisms that govern the formation and dissolution of IF aggregates are poorly defined. In this dissertation, I investigate IF aggregates called Rosenthal fibers (RFs), which form in astrocytes of patients with two pediatric neurodegenerative diseases, Alexander disease (AxD) and Giant Axonal Neuropathy (GAN). My aim was to gain a better understanding of the mechanisms of how astrocyte IF protein aggregates form and interrogate the role of post- translational modifications (PTMs) in this process.
    [Show full text]
  • Routinely Tested Analytes
    FORENSIC TOXICOLOGY LABORATORY OFFICE OF CHIEF MEDICAL EXAMINER CITY OF NEW YORK ROUTINELY TESTED ANALYTES Listed below are drugs that are routinely included in comprehensive toxicology testing and subsequently confirmed and quantitated. (Applicable analytical methodologies are in parentheses.) VOLATILES AND GASES Ethanol (HS/GC) Acetone (HS/GC)Uncontrolled Copy 2-propanol (HS/GC) Methanol (HS/GC) Carbon monoxide (SP, CT) INCLUDED WITH POSITIVE ELISA FOR: 1. Opiates: Morphine, codeine, 6-MAM, hydrocodone, hydromorphone, oxycodone, oxymorphone (LC/MS) 2. Benzoylecgonine: cocaine, benzoylecgonine (LC/MS) 3. Barbiturates: pentobarbital, phenobarbital, secobarbital, amobarbital, butabarbital, butalbital, phenytoin, carbamazepine (HPLC) 4. Benzodiazepines: diazepam, nordiazepam, oxazepam, temazepam, alprazolam, alphahydroxyalprazolam triazolam, clonazepam, 7-aminoclonazepam, lorazepam, 7-amino flunitrazepam (GC/MS) 5. Amphetamines: amphetamine, methamphetamine, MDA, MDMA, MDEA, ephedrine, pseudoephedrine, phenylpropanlolamine, paramethoxyamphetamine. (GC/MS) 6. Oxycodone: see drugs in Opiates above plus acetaminophen (LC/MS, HPLC) 7. Methadone: methadone (and any other drugs indentified from the same extraction. 8. Cannabinoids (as needed): unconfirmed screening test BASED ON HISTORY: Vitreous chemistry: glucose, lithium Carbon monoxide Page 1 of 5 In addition to the above, the following drugs are routinely included in comprehensive toxicology testing with subsequent confirmation and quantitation. (Applicable analytical methodologies are in
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn Et Al
    US 2003.0068365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn et al. (43) Pub. Date: Apr. 10, 2003 (54) COMPOSITIONS AND METHODS FOR Related U.S. Application Data ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME BEADS (60) Provisional application No. 60/327,643, filed on Oct. 5, 2001. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); Tanusin Ploysangam, Bangkok (TH); Publication Classification Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok (51) Int. Cl." .......................... A61K 9/127; A61K 35/78 (TH); Nardo Zaias, Miami Beach, FL (52) U.S. Cl. ............................................ 424/450; 424/725 (US) (57) ABSTRACT Correspondence Address: Law Office of Eric G. Masamori Compositions and methods for administration of active 6520 Ridgewood Drive agents encapsulated within liposome beads to enable a wider Castro Valley, CA 94.552 (US) range of delivery vehicles, to provide longer product shelf life, to allow multiple active agents within the composition, (21) Appl. No.: 10/264,205 to allow the controlled use of the active agents, to provide protected and designable release features and to provide (22) Filed: Oct. 3, 2002 Visual inspection for damage and inconsistency. US 2003/0068365A1 Apr. 10, 2003 COMPOSITIONS AND METHODS FOR toxic degradation of the products, leakage of the drug from ADMINISTRATION OF ACTIVE AGENTS USING the liposome and the modifications of the Size and morphol LPOSOME BEADS ogy of the phospholipid liposome vesicles through aggre gation and fusion. Liposome vesicles are known to be CROSS REFERENCE TO OTHER thermodynamically relatively unstable at room temperature APPLICATIONS and can Spontaneously fuse into larger, leSS Stable altered liposome forms.
    [Show full text]
  • 5-HT Receptors Review
    Neuronal 5-HT Receptors and SERT Nicholas M. Barnes1 and John F. Neumaier2 1Cellular and Molecular Neuropharmacology Research Group, Section of Neuropharmacology and Neurobiology, Clinical and Experimental Medicine, The Medical School, University of Birmingham, Edgbaston, Birmingham B15 2TT UK and 2Department of Psychiatry, University of Washington, Seattle, WA 98104 USA. Correspondence: [email protected] and [email protected] Nicholas Barnes is Professor of Neuropharmacology at the University of Birmingham Medical School, and focuses on serotonin receptors and the serotonin transporter. John Neumaier is Professor of Psychiatry and Behavioural Sciences and Director of the Division of Neurosciences at the University of Washington. His research concerns the role of serotonin receptors in emotional behavior. Contents Introduction Introduction ........................................................................ 1 5-hydroxytryptamine (5-HT, serotonin) is an ancient biochemical manipulated through evolution to be DRIVING RESEARCH FURTHER The 5-HT1 Receptor Family ............................................... 1 utilized extensively throughout the animal and plant kingdoms. Mammals employ 5-HT as a 5-HT Receptors ............................................................ 2 1A neurotransmitter within the central and peripheral nervous systems, and also as a local hormone in 5-HT Receptors ............................................................ 2 1B numerous other tissues, including the gastrointestinal tract, the cardiovascular
    [Show full text]
  • Dalwadi, Dhwanil, A, PREVENTION and TREATMENT of DISEASES: a SMALL MOLECULE DISCOVERY and DEVELOPMENT. Doctor of Philosophy (Bio
    Dalwadi, Dhwanil, A, PREVENTION AND TREATMENT OF DISEASES: A SMALL MOLECULE DISCOVERY AND DEVELOPMENT. Doctor of Philosophy (Biomedical Sciences), August, 2016, 227 pp., 6 tables, 32 illustrations, 256 references. This work examined the structure-activity relationship, and molecular mechanisms of different structural classes of small molecules at their target receptors. Three different systems were explored and each chapter is devoted to a single system. All three systems utilized similar experimental approaches, and practical application of the same core pharmacological principles. The first system involved the evaluation of the structure-activity space of small molecules acting on the α-like octopamine receptors from the barnacle Balanus improvisus (BiOctR) and the fruit fly Drosophila melanogaster (DmOctR). A number of molecules belonging to the imidazole and imidazole structural class were determined to have high potency for the BiOctR and the DmOctR. This information will be useful in designing new OctR ligands that are highly selective for the OctRs over their mammalian off-targets. Similarly, for the second system, the structure-activity space of different structural classes of sigma-1 receptor (S1R) ligands were evaluated. Four novel EPGN compounds with more than 100-fold selectivity for the S1R over the sigma-2 receptor were identified which were able to stimulate S1R-mediated BDNF secretion. Potential therapeutic applications of these compounds include the treatment of neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. The third system involved the identification of receptor off-targets of efavirenz that may be responsible for efavirenz’s neuropsychiatric adverse events (NPAEs). In this study, multiple receptor targets of efavirenz belonging to the serotonin receptor family and the muscarinic receptor family of G protein-coupled receptors (GPCR) were identified, and its mechanism of action at these targets was established.
    [Show full text]
  • Novel Analogs of M-Chlorophenylguanidine As 5-HT3 Receptor Ligands
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2009 Novel Analogs of m-Chlorophenylguanidine as 5-HT3 Receptor Ligands Katie Alix Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Chemicals and Drugs Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/1734 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. © Katie Elizabeth Alix 2008 All Rights Reserved NOVEL ANALOGS OF m-CHLOROPHENYLGUANIDINE AS 5-HT3 RECEPTOR LIGANDS A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University. by KATIE ELIZABETH ALIX Bachelor of Science in Biochemistry, Virginia Tech 2006 Bachelor of Arts in Chemistry, Virginia Tech 2006 Director:MAŁGORZATA DUKAT Associate Professor, Department of Medicinal Chemistry Virginia Commonwealth University Richmond, Virginia May 2009 Acknowledgement First, I would like to thank Dr. Dukat for her patience and guidance over the last three years. She has helped mold me into a better scientist with a deeper understanding and appreciation of medicinal chemistry as an entire discipline. I would like to thank Dr. Richard Glennon for his help with my thesis and numerous useful insights. I would also like to thank Dr. Richard Young, Jessica Worsham, and Genevieve Sirles for teaching me how to handle mice and the various animal assays. I would also like to thank Dr.
    [Show full text]